Tumors reprogram the liver, causing wasting and short-circuiting body's immune response

November 8, 2016, Cold Spring Harbor Laboratory

One of the worst cruelties of lethal cancer is the phenomenon called wasting, or in medical terms, cachexia (pronounced ka-CHEX-ia), in which a patient seems literally to diminish in bodily terms as the cancer ravages one or more internal organs.

Today, a team at Cancer Research UK Cambridge Institute, led by Professor Douglas Fearon, M.D., of Cold Spring Harbor Laboratory in New York and a Distinguished Scholar of the Lustgarten Foundation, publishes in Cell Metabolism results of experiments showing that tumors interfere with the patient's ability to cope with wasting and may even impair their ability to respond to immunotherapy.

In mouse models of human pancreatic and colon cancer, the team traces cachexia to a molecular reprogramming of the liver induced by the tumor, the effect of which is to alter the liver's normal response to caloric deficiency. As the caloric deficiency worsens and weight continues to decline, the body responds by releasing stress hormones. The team found that these hormones, in turn, prevent the immune system from responding to the tumor.

Thus the new research helps explain two ways in which pancreatic and colon tumors have long vexed doctors attempting to treat them: these tumors themselves set in motion the process that results in wasting; and wasting, in turn, accounts for why for such cancers has typically failed. Providing massive caloric supplementation - what doctors call hyperalimentation - does not vanquish wasting; and immune therapy does not impair the tumor's ability to thrive.

The researchers in Cambridge, led by M.D.-Ph.D. student Thomas R. Flint and oncologist Tobias Janowitz, M.D., Ph.D., performed experiments demonstrating that in mouse models of pancreas and , liver reprogramming begins during pre-cachexia, when wasting has just begun but is not yet manifest. Signals broadcast by tumor cells induce the release of interleukin 6 (IL-6), a molecular beacon of the immune system called a cytokine, that normally helps induce an immune response. IL-6, in turn, impairs the capacity of the liver to respond to caloric deprivation, which is already under way in pre-cachectic mice.

The team proposes this liver reprogramming is the result of IL-6 suppressing a gene-regulating protein, or transcription factor, called PPAR-alpha, which in turn suppresses a vital process in the liver called ketogenesis. "Translated into human terms, this means that when a cancer patient loses his or her appetite and decides not to eat, the liver is not going to generate sufficient energy to compensate for the caloric loss," explains Dr. Fearon.

Often, cancer patients don't eat, Dr. Fearon clarifies, not because they are nauseous due to chemotherapy; rather, they feel full and simply lose their appetite. Importantly, he adds, his team's discovery that the tumor is programming the liver not to make calories, which are essential for continued brain function, assures two things. One is that wasting will continue; the other is that the body, massively releasing glucocorticoids, or stress hormones, will thereby short-circuit the immune system's ability to respond to the tumor. It's a vicious circle that sadly ends in death.

The team's discovery not only sheds light on why conventional caloric supplementation fails to curtail cachexia in cancer patients. It also helps to account for the failure of T-cell checkpoint targeted immunotherapies in pancreatic and colon cancers. The tumor, in effect, is

fooling the immune system into thinking the is not a threat but rather just normal regenerating tissue. The team tested several ways of addressing liver reprogramming in pre-cachectic mice. Using a that recapitulates human pancreatic cancer, they administered an antibody that targets and inactivates IL-6; the same mice received massive caloric supplements via infusion. According to Dr. Flint, "Our data suggest that successful reversal of cachexia in people may well depend on co-administration of anti-IL-6 with nutritional support."

The team also noted that their findings may have relevance in a wide range of IL-6-associated illnesses in which weight loss in observed. These include sepsis, HIV, tuberculosis, chronic obstructive pulmonary disease, cardiac failure and rheumatoid arthritis.

Explore further: Molecularly shutting down cancer cachexia

More information: "Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity" Cell Metabolism; 8 Nov 2016; DOI: 10.1016/j.cmet.2016.10.010

Related Stories

Molecularly shutting down cancer cachexia

August 30, 2016
Healthy fat tissue is essential for extended survival in the event of tumor-induced wasting syndrome (cachexia). In Nature Medicine, researchers at Helmholtz Zentrum München show that selective manipulation of an enzyme ...

Research uncovers defender against cancer-promoting liver damage

October 10, 2016
Most cases of liver cancer develop after long-term viral infection, chronic exposure to alcohol, or excessive accumulation of fat in the liver due to obesity. The liver reacts to those insults by trying to wall it off with ...

Adding immunotherapy to RFA may benefit colorectal cancer patients with liver metastasis

March 1, 2016
Radiofrequency ablation (RFA), a procedure to treat liver metastases in patients with colorectal cancer, was found to induce antitumor immune responses in human samples of primary colon tumor, and mice treated with a combination ...

Cancer wasting due in part to tumor factors that block muscle repair, study shows

October 23, 2013
A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting. The condition, also called cancer cachexia, ...

Study suggests that autophagy inhibitors could improve efficacy of chemotherapies

October 24, 2016
Chemotherapies treat cancer by killing tumor cells, but certain types of chemotherapy can also drive an immune system response to target and destroy the remaining tumor cells.

Liver controls wasting in cancer: Overactive gene switch in the liver causes blood fat levels to drop

January 14, 2013
Many cancer patients suffer from a dramatic loss of fat and muscle mass. This extreme wasting, or cachexia, is often the actual cause of death in cancer patients. Heidelberg scientists have now discovered in mice that tumors ...

Recommended for you

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

Researchers develop mechanism for characterizing function of rare tumor cells

September 17, 2018
Scientists have long known that circulating tumor cells, rare cancer cells that are released into the bloodstream, have the potential to provide vital information about a person's specific cancer. But until now, they have ...

Artificial intelligence can determine lung cancer type

September 17, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.

Nanoparticle therapeutic restores function of tumor suppressor in prostate cancer

September 17, 2018
Think of it as a cancer therapy zag instead of a zig. While many groups are developing cancer therapies to target proteins and pathways that are highly active in cancer cells, a team of investigators from Brigham and Women's ...

Crested cactuses inspire researchers to look for new ways to control cancer

September 17, 2018
Sun Tzu, the general of ancient China, wrote in his enduring military treatise "The Art of War" of the importance of knowing one's enemy. The idea resonates strongly with Athena Aktipis, a scholar of many titles at Arizona ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.